| Variable | Control (n = 12) | Cases (n = 68) | p |
| Age (y) | 53.5 ± 9.5 | 55.3 ± 10 | 0.569 |
| Sex |
|
|
|
| Male, n, (%) | 5 (41.7%) | 40 (58.8%) | 0.269 |
| Female, n, (%) | 7 (58.3%) | 28 (41.2%) |
|
| BMI (kg/m2) | 26.7 ± 3.2 | 28.3 ± 3.6 | 0.143 |
| HTN, n, (%) | 3 (25%) | 31 (45.6%) | 0.269 |
| DM, n, (%) | 4 (33.3%) | 29 (42.6%) | 0.752 |
| FBS (mg/dl) | 5 (41.7%) | 36 (52.9%) | 0.471 |
| Dyslipidemia, n, (%) | 2 (16.7%) | 15 (22.1%) | 1.000 |
| FH of CAD, n, (%) | 4 (33.3%) | 27 (39.7%) | 0.758 |
| Smoking, n, (%) | 57.5 ± 4.4 | 57.1 ± 4.4 | 0.748 |
| LVEF% | 1.09 ± 0.29 | 1.1 ± 0.3 | 0.802 |
| Creatinine (mg/dl) | 102.4 ± 20.4 | 111 ± 24.5 | 0.254 |
| LDL-C (mg/dl) | 133.7 ± 29.4 | 135 ± 34.8 | 0.901 |
| HDL-C (mg/dl) | 38.8 ± 8.3 | 39.8 ± 8.4 | 0.716 |
| TG (mg/dl) | 142.9 ± 56 | 153.5 ± 65.2 | 0.509 |
| TCH (mg/dl) | 201.2 ± 34.8 | 206.9 ± 37.5 | 0.623 |
| Pentraxin-3 (ng/ml) | 3.1 ± 0.9 | 3.9 ± 1.4 | 0.038 |
| SYNTAX score | - | 15.8 ± 11.3 |
|